Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
Learn more about biosimilars and their benefits for patients and healthcare systems.
Biosimilars Canada is participating in this globally aligned educational initiative to raise awareness of biosimilar medicines from November 16 to 20.
A new study by the Ontario Drug Policy Research Network found that provinces could save up to $426 million by implementing biosimilar switching policies.
Op-ed in Advantages magazine by Jim Keon, President of the Canadian Generic Pharmaceutical Association and its Biosimilars Canada division, which highlights the benefits of expanding the use of generic and biosimilar medicines for group drug benefit plans. Available in French only.